Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030–3.
2. Kim C, Prasad V. Strength of validation for surrogate end points used in the US Food and Drug Administration’s approval of oncology drugs. Mayo Clin Proc. 2016; doi:
10.1016/j.mayocp.2016.02.012
.
3. Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol. 2012;23:1646–51.
4. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49–67.
5. Institute for Quality and Efficiency in Health Care. . Validity of surrogate endpoints in oncology: executive summary of rapid report A10–05, version 1.1. Cologne, Germany: Institute for Quality and Efficiency in Health Care; 2005.
Cited by
185 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献